Tenecteplase for Acute Ischemic Stroke - Live

November 23, 2021

Intravenous thrombolytics is the mainstay of acute therapy in ischemic stroke.  While alteplase has been FDA-approved for this indication since the 1990s, Tenecteplase has recently gained traction for usage in acute ischemic stroke treatment as well.  This lecture summarizes the existing evidence and practical considerations for use of Tenecteplase in stroke therapy.  

Target Audience

ED Physicians

Internal Medicine Physicians

Nurses

Stroke Coordinators

Learning Objectives

Learners will be able to:

  • define the usage of tenecteplase for acute ischemic stroke
  • assess the utility of tenecteplase as an alternative to alteplase in the correct clinical setting
  • analyze some of the data from major tenecteplase trials
  • demonstrate knowledge of proper tenecteplase administration techniques and protocols
Course summary
Course opens: 
10/11/2021
Course expires: 
11/23/2021
Event starts: 
11/23/2021 - 12:00pm EST
Event ends: 
11/23/2021 - 1:00pm EST
Add to calendar: 
Rating: 
0
Speaker(s)

Benzion Blech, M.D.

has no relevant financial relationships to disclose at this time.
Course Director(s)

Vahid Behravan, M.D.

has a financial relationship (Employment) with Johnson&Johnson;.
Peer Reviewer(s)

Vahid Behravan, M.D.

has a financial relationship (Employment) with Johnson&Johnson;.

Michelle Boudreau, D.O.

has no relevant financial relationships to disclose at this time.

 

We are working with a Joint Provider to provide CME accredited activities.  Please allow up to 10 business days for your instructions on claiming your CME certificate. 

Please login or register to take this course.